Unlike blood specimen collection,
Metascreen® is a non-invasive procedure

Unlike other newborn tests in the market, Metascreen® is a simple and non-invasive urine test to screen more than 100 metabolic disorders without causing any harm or discomfort to your baby. Screening your newborn will facilitate early treatment and prevent long term detrimental effects to your baby’s health.

Reliably Detects More Than 100 Metabolic Disorders

FDA-approved GC-MS technology combined with proprietary bioinformatics to reliably detect more than 100 metabolic disorders.

Simple And Painless Urine Test

Your baby’s urine can be easily collected by inserting filter paper into the diaper without causing any harm or discomfort to your baby.

Suitable To Babies Up To 6 Months

Screen your baby from 48 hours after birth, up until 6 months of age. Ideally, your baby should be screened between 2 to 7 days.
after birth

Timely Screening Report

The results will be available within 10-14 working days to enable early treatment, if necessary.

Unlike blood specimen collection, Metascreen® is a non-invasive procedure

Metascreen® is the most comprehensive newborn metabolic screening. Unlike other newborn tests in the market, Metascreen® is a simple and non-invasive urine test to screen more than 100 metabolic disorders without causing any harm or discomfort to your baby. Screening your newborn will facilitate early treatment and prevent long term detrimental effects to your baby’s health.

Reliably detects more than 100 metabolic disorders

FDA-approved GC-MS technology combined with proprietary bioinformatics to reliably detect more than 100 metabolic disorders.

Simple and painless urine test

Your baby’s urine can be easily collected by inserting filter paper into the diaper without causing any harm or discomfort to your baby.

Suitable to babies up to 6 months

Screen your baby from 48 hours after birth, up until 6 months of age. Ideally, your baby should be screened between 2 to 7 days.
after birth

Timely screening report

The results will be available within 10-14 working days to enable early treatment, if necessary.

International accreditation

The laboratory is located at Hong Kong Science and Technology Park and accredited by The College of American Pathologists (CAP), which has stringent standards for laboratory operations, quality and technology.

Highly Accurate & Specific

Metascreen® uses a gas-chromatography mass spectrometry (GC-MS) technology manufactured by Shimadzu, Japan. After processing the urine specimen through GC-MS, we analyse the GC-MS data using proprietary planar bioinformatics first developed by Japanese researchers. The planar bioinformatics makes use of multiple analytes (metabolites) from more than one biochemical (metabolic) pathway to identify a single metabolic disorder. This means that the results would be more reliable and accurate than traditional technology using mass tandem spectrometry (MS-MS) because MS-MS only uses about 1 or 2 analyte profiles for each disorder, and often, the same analyte profile is used for multiple disorders.

Highly Reliable Testing Platform

Using FDA-approved GC-MS technology, Metascreen® is a non-invasive urine test that screens more than 100+ metabolic disorders without causing any harm or discomfort to your baby. As many metabolic disorders are organic acid disorders (also known as “organic acidemias”), they can be detected more accurately using urine, based on the abnormal excretion patterns of the metabolites as a result of faulty metabolism caused by the disorder. Because our kidneys can efficiently remove unwanted or toxic metabolites from the blood, such compounds are excreted in large amounts in the urine, but may not be found in significant concentrations in blood.1

The American College of Medical Genetics (ACMG) actually recommends urine organic analysis as the diagnosis step for many of metabolic disorder, should there be a positive newborn screening result using the dried blood spot analysed by tandem mass spectrometry (MS/MS).2,3

  GC-MS technology MS-MS technology
Invasiveness Baby’s urine Baby’s bloods from heel prick
Number More than 100 disorders Around 20-30 disorders
Accuracy rate 99%3
 Higher false positive (0.07- 3.00%)4
Specificity Specific result using multiple analyte profiles Confirmatory test is needed for verification
Time to diagnose From screening and confirmation to diagnosis From screening to confirmation then finally to diagnosis

Enroling Metascreen®

Your baby’s first step to a healthy life. Enrolling Metascreen® for your baby now, the only non-invasive comprehensive newborn screening that detects more than 100+ metabolic disorders.

Enrolment

Call us for service enrolment and get collection kit .

Sample collection

Collect your baby’s urine sample when baby is at least 2 days old and has taken at least one feed 24 hours ago.

Sample Pick-up

Call our hotline and courier service will be arranged for sample pick up.

Testing & Analysis

Your baby’s urine sample will be screened and analysed for metabolic disorders using GC-MS technology.

Reporting & follow up

We will arrange a follow up consultation if the test result is positive.

Metascreen® Enrolment Process

Enrolling Metascreen® for your baby now, the only non-invasive comprehensive newborn screening that detects more than 100+ metabolic disorders.

Enrolment

Call us for service enrolment and get collection kit

Sample Collection

Collect your baby’s urine sample when baby is at least 2 days old and has taken at least one feed 24 hours ago.

Sample Pick-up

Call our hotline and courier service will be arranged for sample pick up.

Testing & Analysis

Your baby’s urine sample will be screened and analysed for metabolic disorders using GC-MS technology.

Reporting & Follow Up

We will arrange a follow up consultation if the test result is positive.


In Malaysia, collectively about 1 in every 4000 individuals5 is expected to be affected with a metabolic disorder.
Screening your newborn will facilitate early treatment and prevent long term detrimental effects to your baby’s health.


Disclaimer

Metascreen® is a trademark or registered trademark of Cordlife Group Limited, a Singapore Exchange Mainboard listed company. The screening test offered under the brand is conducted by Cordlife (Hong Kong) Ltd., laboratory committed to providing early and accurate detection of metabolic disorders in newborn babies. Cordlife (Hong Kong) Ltd. has a quality management system in place to ensure maximum accuracy of screening results. As with any laboratory tests, false positive or false negative results cannot be completely eliminated due to various reasons including but not limited to age of patient at the time of specimen collection, patient’s health status, specimen quality and other variables. Hence, the risk of a disorder should never be precluded solely on the basis of screening. Signs or symptoms observed should be followed up immediately by a professional healthcare provider.

Reference :
1) Evaluation of the 18-month "Pilot Study of Newborn Screening for Inborn Errors of Metabolism" in Hong Kong. HK J Paediatric (New Series). 2020;25:16-22
2) Michael J. Laboratory Medicine Practice Guidelines. Follow-up Testing for Metabolic Diseases Identified by Expanded Newborn Screening Using Tandem Mass Spectrometry. The National Academy of Clinical Biochemistry. 2009
3) Based on internal data, as of June 2020.
4) D. Matern, K. Raymond, S. Tortorelli, et al. Improving NBS Performance: The Mayo Clinic Experience Report.
5) Inborn Errors Of Metabolism (IEM). MyHealthh Kementerian Kesihatan Malaysia Website. http://www.myhealth.gov.my/en/inborn-errors-of-metabolism/. Accessed April 2020.

SBT/PM-042/Rev.00